Algeta selects new Board of Directors

Dr. Judith Hemberger and Dr. Kapil Dhingra were elected to Algeta's Board of Directors as Non-executive Directors at the Company's annual general meeting held in Oslo on 22 April 2010.

Judith Hemberger, Ph.D. (age 62), is an experienced biotech industry executive with more than 30 years' of global pharmaceutical and biotech industry experience. Dr. Hemberger was a co-founder, Executive Vice President and Chief Operating Officer of Pharmion Corporation since its inception in 2000 until 2006. Prior to that, she served as Senior Vice President of Business Development at AVAX Technologies, Inc., a vaccine technology company.

More recently, Dr Hemberger was a Venture Partner at Nomura Phase4 Ventures (2006-2009) and Interim CEO of Zosano Pharma, Inc. She currently serves on the board of directors of VasoGenix Pharmaceuticals, Inc. and Chroma Therapeutics, and has previous board experience with Marion Merrell Dow, NexStar Pharmaceuticals, Cell Pathways, Schein, Pharmion, PRA International, Perrigo, Renovis, Myogen, Zosano Pharma, Novacea, Health Shares, Zymogenetics, and Atani.

Kapil Dhingra M.B., B.S., (age 50), is formerly Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development at Hoffmann-La Roche, at which he worked between 1999-2008. For three years prior to this, he worked as a Clinical and Senior Clinical Research Physician with Eli Lilly and Company, and from 1989 to 1996 he was a Clinical Instructor, Assistant Professor of Medicine at the University of Texas M.D. Anderson Cancer Center.

Throughout his industry career, Dr. Dhingra maintained an active faculty appointment, initially at Indiana University School of Medicine from 1997 to 1999 as Clinical Associate Professor, and, more recently, at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008.
 
Stein Annexstad, Chairman of Algeta, said: "We are very pleased to welcome Judy and Kapil to the Algeta Board. Between them, they have a wealth of experience in the US and global pharma industry and particularly in the clinical and commercial development of innovative targeted cancer therapies".

The new board of directors of Algeta consists of the following members: Stein Annexstad (chairman), John E. Berriman (deputy chairman), Kapil Dhingra, Judith Hemberger, Hilde Hermansen Steineger, Ingrid Wiik, Joe Anderson, and Per Samuelsson.

More information on Altega's website